Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2900MR)

This product GTTS-WQ2900MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2900MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12657MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ12839MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ536MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ15473MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ11262MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ3969MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ12211MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ6547MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA D2E7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW